What is the history of Macular Degeneration?

Macular degeneration, specifically age-related macular degeneration (AMD), was first identified in the mid-19th century and has evolved from being considered an untreatable sign of aging to a condition managed with targeted medical therapies. While early descriptions focused on the physical appearance of the retina, modern understanding now integrates complex genetic, environmental, and vascular factors to guide life-changing treatments.

When and how was macular degeneration first described?

The clinical recognition of macular degeneration began in 1851 with the invention of the ophthalmoscope by Hermann von Helmholtz. Shortly thereafter, in 1874, British ophthalmologist Robert Brudenell Carter provided one of the first detailed descriptions of the condition. Later, in 1885, Otto Haab described the "senile macular changes," which laid the foundation for recognizing macular degeneration as a distinct clinical entity rather than just a natural, unavoidable consequence of growing older.

How has our understanding of macular degeneration evolved?

For decades, macular degeneration was viewed as a singular, monolithic disease. However, medical researchers eventually characterized the condition into two primary forms: "dry" (atrophic) and "wet" (neovascular). A major shift occurred in the early 2000s when researchers identified the role of Vascular Endothelial Growth Factor (VEGF) in the "wet" form of macular degeneration. This discovery transformed the disease from a condition with no viable treatment into one manageable with anti-VEGF injections.

What are the major milestones in treatment development?

The treatment landscape for macular degeneration has seen remarkable progress over the last century:

• 1980s: Introduction of laser photocoagulation to seal leaking blood vessels.


• 2000s: The development of Photodynamic Therapy (PDT) using verteporfin.


• 2006: FDA approval of ranibizumab, the first major anti-VEGF therapy that revolutionized outcomes.


• 2020s: Implementation of advanced imaging like Optical Coherence Tomography (OCT) for precise monitoring.

How has genetics changed our knowledge of the disease?

Modern genetic research has revealed that macular degeneration has a strong hereditary component, specifically involving genes related to the complement system, such as CFH and ARMS2. These findings have moved us away from historical misconceptions that macular degeneration was purely lifestyle-driven, allowing for more personalized risk assessments and the development of targeted clinical trials.

Next steps

• Schedule a comprehensive dilated eye exam with a retina specialist.


• Connect with the 9 members of the DiseaseMaps community currently navigating macular degeneration.


• Discuss current clinical trials for geographic atrophy and advanced AMD with your ophthalmologist.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• National Eye Institute (NEI): Age-Related Macular Degeneration (AMD) Fact Sheet.


• NIH Genetic and Rare Diseases Information Center (GARD).


• American Academy of Ophthalmology (AAO): History of Macular Degeneration.


• Orphanet: Rare eye disease database.